We are pleased to announce the release of a groundbreaking research paper titled "Characterisation of the Cardiovascular Effects of a Meal: QTcF Assessment and Further Insights into the Physiological Effects," authored by Dr. Georg Ferber, Dr. Dilshat Djumanov, Dr. Ulrike Lorch, Dr. Edward Jackson, Dr. Joao Almeida Melo, Mr. James Rickard, and Dr. Jorg Taubel. 

This collaborative effort between Statistik Georg Ferber GmbH, Richmond Pharmacology Ltd, St George’s University of London, King’s College London and Richmond Research Institute delves into the intricate relationship between meals and the QT interval on an electrocardiogram (ECG), particularly when corrected for heart rate using Fridericia's formula (QTcF). 

The study explores the impact of meals on QTcF intervals in the context of integrating Pharmacology studies and Thorough QT (TQT) investigations, providing crucial insights into the potential implications for cardiac health and the risk of arrhythmias. The comprehensive meta-analysis, based on data from nine studies conducted in accordance with ethical standards, sheds light on meal effect QTcF changes, offering valuable perspectives for cardiac safety assessment in clinical trials and drug development. 

The findings also hold promise for more patient-focused practices, contributing to the global fight against antimicrobial resistance (AMR) through the potential reduction of exposure to harmful challenge agents. This research marks a significant step forward in our understanding of the impact of meals on cardiovascular health and aims to accelerate the pace and safety of drug development processes.

Latest news

Von Willebrand Disease – First Stage of Hemab Therapeutics’ Trial Completed and New Patients Invited to Enrol

April 2, 2025
Richmond has completed dosing the first cohort of patients in Velora Pioneer, a phase 1/2 clinical trial investigating Hemab...
Read more

First patient enrolled in telehealth study, the Pathway Study

February 25, 2025
The Pathway study is based on pioneering work during the pandemic between clinicians at Richmond Pharmacology and the National Amyloidosis Centre and aims...
Read more

Events

CRISPR Medicine 2025: Unlocking Gene-Editing Potential

April 7–11
Exploring advancements shaping the future of healthcare.
View event